A provider tells the nurse a client with a peptic ulcer is being placed on a proton pump inhibitor. Which medication would the nurse anticipate the provider ordering?

Choice A reason: Omeprazole, a proton pump inhibitor, reduces gastric acid production by irreversibly inhibiting the H+/K+-ATPase enzyme in parietal cells. This decreases acid-related damage to the gastric mucosa, promoting healing of peptic ulcers. It is highly effective for H. pylori-associated ulcers when combined with antibiotics, making it a standard choice for peptic ulcer treatment. Choice B reason: Ranitidine, an H2 receptor antagonist, reduces acid secretion by blocking histamine receptors on parietal cells. While effective for mild ulcers, it is less potent than proton pump inhibitors like omeprazole for severe cases or H. pylori-related ulcers. It is not the first-line choice for peptic ulcer disease in most modern treatment protocols. Choice C reason: Sucralfate forms a protective barrier over the ulcer, shielding it from acid and pepsin, promoting healing. It does not reduce acid production, unlike proton pump inhibitors. While useful as an adjunct, it is not a proton pump inhibitor, so it would not be the anticipated medication in this context. Choice D reason: Metronidazole is an antibiotic used in H. pylori eradication regimens, often combined with proton pump inhibitors and other antibiotics. It does not reduce gastric acid or directly treat ulcers. Its role is to eliminate bacterial infection, not to inhibit acid production, so it is not classified as a proton pump inhibitor.